Current development efforts in IVIG are focused on novel immunoglobulin administration routes that can overcome the limitations of intramuscular administration.
The use of intravenous immunoglobulin (IVIG) has grown exponentially in recent years, with IVIG increasingly being used to treat various diseases. The increase in IVIG use in autoimmune disease states has helped to reduce the burden and prevalence of primary immunodeficiency (PID) diseases, leading to greater growth opportunities in the IVIG market, which could reach $20 in the next decade .5 billion, according to a report from Transparency Market Research.
The report notes that the expansion of the targeted IVIG patient population has led to research and development efforts, particularly in innovative purification and manufacturing methods, with IV routes of administration achieving greater clinical acceptance for some drugs, especially for use in children. Current development efforts in IVIG are focused on new routes of immunoglobulin administration that can overcome the limitations of intramuscular administration.
Multiple clinical studies have attempted to evaluate the use of IVIG in the treatment of SARS-CoV-2 virus. Additional studies are underway to improve the safety and tolerability of IVIG for symptomatic secondary immunodeficiency, autoinflammatory diseases and C1 inhibitor deficiency, which could reveal promising new treatment pathways, according to the report. The analysis further noted that the prospects for the IVIG market are enhanced by randomized trials evaluating the efficacy of immunoglobulin replacement therapy in the treatment of primary antibody deficiency (PAD).
The analysis found that increased use of IVIG is driven by significant demand for these products in the treatment of patients with antibody deficiencies, particularly for PAD. In particular, a growing need for treatments for hypogammaglobinemia has provided significant revenue opportunities for manufacturers of IVIG products, according to the report.
As the acceptance of IVIG replacement therapy has increased for a range of antibody deficiency diseases, the need for novel IVIG preparations has also increased. These possibilities are augmented by the high incidence of PID and recurrent infections, illustrating the need for effective treatments for this indication. According to Transparency Market Research, use of IVIG has also increased in hospital settings, the preferred place of treatment for immunodeficiency disorders. The authors wrote that higher attendance numbers in hospitals versus independent clinics helped this segment account for the leading share of the global IVIG market last year.
The main drivers of IVIG research are the prevalence of PAD syndromes and the high burden on the patient population. The report notes that advancements in routes of administration and the growth of clinical research on the safety and efficacy of immunoglobin products have expanded opportunities in this area.
Intravenous Immunoglobulin Market Advances at CAGR of 7.3% in 2022-2031: TMR Study. Transparency Market research. news item. Accessed June 15, 2022. https://www.globenewswire.com/news-release/2022/05/30/2452494/0/en/Intravenous-Immunoglobulin-Market-to-Advance-at-CAGR-of-7- 3-During-2022-2031-TMR-Study.html